CD39+IBDinfliximab

Alexander Schnell1, Benedikt Schwarz2, Hannah Schmidt3

  • 1Pediatric Gastroenterology and Hepatology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany alexander.schnell@uk-erlangen.de.

Life science alliance
|April 8, 2025
PubMed
概括

在B细胞上的CD39和CD73调节免疫反应. 在儿科炎症性肠病 (IBD) 中,B细胞的CD39表达增加与成功的因弗力西马布 (IFX) 治疗相关,这表明治疗生物标志物.